Institut de Recherches Servier
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$855,012
Doctors Paid
0
Transactions
54
2021 Total
$793,526
Payment Breakdown by Category
Research$793,526 (92.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $793,526 | 52 | 92.8% |
| Space rental or facility fees (teaching hospital only) | $61,486 | 2 | 7.2% |
Payments by Type
Research
$793,526
52 transactions
General
$61,486
2 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| CALASPARGASE PEGOL IN ADULTS WITH ALL | $777,728 | 0 | 16 |
| PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (SUNLIGHT) | $10,403 | 0 | 31 |
| AN INTERNATIONAL PHASE IB MULTICENTRE STUDY TO CHARACTERIZE THE SAFETY AND TOLERABILITY OF INTRAVENOUSLY ADMINISTERED S64315, A SELECTIVE MCL-1 INHIBITOR, IN COMBINATION WITH ORALLY ADMINISTERED VENETOCLAX, A SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) | $5,395 | 0 | 5 |
Top Paid Doctors
No doctor payment records found.
About Institut de Recherches Servier
Institut de Recherches Servier has made $855,012 in payments to 0 healthcare providers, recorded across 54 transactions in the CMS Open Payments database. In 2021, the company paid $793,526. The top product by payment volume is ASPARLAS ($777,728).
Payment categories include: Research ($793,526).